AI Article Synopsis

  • Integrated analysis of biomarkers like IL-6 and iron regulatory genes helps manage Japanese encephalitis (JEV) infections.
  • The study showed elevated IL-6 levels and increased expression of iron-related genes (hepcidin, transferrin, transferrin receptor) in JEV cases.
  • Additionally, a specific genetic variation in the transferrin gene is linked to clinical symptoms and varying severity of JEV infections among individuals.

Article Abstract

Integrated analysis of iron regulatory biomarkers and inflammatory response could be an important strategy for Japanese encephalitis viral (JEV) infection disease management. In the present study, the inflammatory response was assessed by measuring serum Interleukin-6 (IL-6) levels using ELISA, and the transcription levels of iron homeostasis regulators were analyzed via RT-PCR. Furthermore, inter-individual variation in the transferrin gene was analyzed by PCR-RFLP and their association with clinical symptoms, susceptibility, severity, and outcomes was assessed through binary logistic regression and classification and regression tree (CART) analysis. Our findings revealed elevated levels of IL-6 in serum as well as increased expression of hepcidin (HAMP), transferrin (TF), and transferrin receptor-1 (TFR1) mRNA in JEV infection cases. Moreover, we found a genetic variation in TF (rs4481157) associated with clinical symptoms of meningoencephalitis. CART analysis indicates that individuals with the wild-type TF genotype are more susceptible to moderate JEV infection, while those with the homozygous type are in the high-risk group to develop a severe JEV condition. In summary, the study highlights that JEV infection induces alteration in both IL-6 levels and iron regulatory processes, which play pivotal roles in the development of JEV disease pathologies.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12017-023-08762-1DOI Listing

Publication Analysis

Top Keywords

jev infection
16
il-6 levels
12
iron regulatory
12
regulatory biomarkers
8
japanese encephalitis
8
inflammatory response
8
levels iron
8
clinical symptoms
8
cart analysis
8
jev
6

Similar Publications

Japanese encephalitis virus (JEV) is a neurotropic zoonotic pathogen that poses a serious threat to public health. Currently, there is no specific therapeutic agent available for JEV infection, primarily due to the complexity of its infection mechanism and pathogenesis. Extracellular vesicles (EVs) have been known to play an important role in viral infection, but their specific functions in JEV infection remain unknown.

View Article and Find Full Text PDF

Japanese encephalitis virus (JEV), a neuroinvasive and neurovirulent orthoflavivirus, can be prevented in humans with the SA14-14-2 vaccine, a live-attenuated version derived from the wild-type SA14 strain. To determine the viral factors responsible for the differences in pathogenicity between SA14 and SA14-14-2, we initially established a reverse genetics system that includes a pair of full-length infectious cDNAs for both strains. Using this cDNA pair, we then systematically exchanged genomic regions between SA14 and SA14-14-2 to generate 20 chimeric viruses and evaluated their replication capability in cell culture and their pathogenic potential in mice.

View Article and Find Full Text PDF

Japanese encephalitis virus (JEV) is regarded as an emerging and reemerging pathogen that is a primary cause of viral encephalitis in humans. However, there is a scarcity of research on the prevalence of JEV genotypes across the different mosquito species in Shanghai. In this study, the diversity of mosquito species and prevalence of JEV in pig and sheep farms in Shanghai were surveyed in 2022.

View Article and Find Full Text PDF

Introduction: Japanese encephalitis virus (JEV) and Zika virus (ZIKV) are prevalent in over 80 countries or territories worldwide, causing hundreds of thousands of cases annually. But currently there is a lack of specific antiviral agents and effective vaccines.

Methods: In the present study, to identify human neutralizing monoclonal antibody (mAb) against JEV or/and ZIKV, we isolated ZIKV-E protein-binding B cells from the peripheral venous blood of a healthy volunteer who had received the JEV live-attenuated vaccine and performed 10× Genomics transcriptome sequencing and BCR sequencing analysis, we then obtained the V region amino acid sequences of a novel mAb LZY3412.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!